These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15027508)

  • 21. Sample size calculation based on efficient unconditional tests for clinical trials with historical controls.
    Shan G; Moonie S; Shen J
    J Biopharm Stat; 2016; 26(2):240-9. PubMed ID: 25551261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [How to assess the size of a clinical trial?].
    Paesmans M
    Rev Mal Respir; 1994; 11(6):547-57. PubMed ID: 7831504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameter estimation following an adaptive treatment selection trial design.
    Luo X; Wu SS; Xiong J
    Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bias of estimates of the number needed to treat.
    Duncan BW; Olkin I
    Stat Med; 2005 Jun; 24(12):1837-48. PubMed ID: 15806616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
    Hutson AD
    Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
    Bryant J; Day R
    Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
    Heller G; Kattan MW; Scher HI
    Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exact and approximate unconditional confidence intervals for proportion difference in the presence of incomplete data.
    Tang ML; Ling MH; Tian GL
    Stat Med; 2009 Feb; 28(4):625-41. PubMed ID: 19035467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power and sample size determination for noninferiority trials using an exact method.
    Chan IS
    J Biopharm Stat; 2002 Nov; 12(4):457-69. PubMed ID: 12477069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimization of sample size when comparing two small probabilities in a non-inferiority safety trial.
    de Boo TM; Zielhuis GA
    Stat Med; 2004 Jun; 23(11):1683-99. PubMed ID: 15160402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian sample size for exploratory clinical trials incorporating historical data.
    Whitehead J; Valdés-Márquez E; Johnson P; Graham G
    Stat Med; 2008 Jun; 27(13):2307-27. PubMed ID: 18069728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of multiple response rates in phase II clinical trials with missing observations.
    Chang M
    J Biopharm Stat; 2009 Sep; 19(5):791-802. PubMed ID: 20183444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A type of sample size design in cancer clinical trials for response rate estimation.
    Liu J
    Contemp Clin Trials; 2011 Jan; 32(1):140-6. PubMed ID: 20965278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculations for a split-cluster, beta-binomial design in the assessment of toxicity.
    Hendriks JC; Teerenstra S; Punt-Van der Zalm JP; Wetzels AM; Westphal JR; Borm GF
    Stat Med; 2005 Dec; 24(24):3757-72. PubMed ID: 16320284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early stopping clinical trials of binomial response with an exact group sequential method.
    Zhao Z
    Stat Med; 2007 Apr; 26(8):1724-9. PubMed ID: 17206748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One- and two-stage designs for stratified phase II clinical trials.
    London WB; Chang MN
    Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.